News

Strata Oncology Announces Collaboration with Epizyme to Support Tazemetostat Clinical Development

Strata Oncology Announces Collaboration with Epizyme to Support Tazemetostat Clinical Development

Epizyme to Participate in Strata Trial for Tazemetostat Phase 2 NHL Trial Enrollment

Ann Arbor, Michigan, February 6, 2017 – Strata Oncology, a precision oncology company, today announced an agreement with Epizyme to support patient identification and enrollment for Epizyme’s ongoing Phase 2 clinical trial of tazemetostat in patients with relapsed or refractory non-Hodgkins lymphoma (NHL).

Tazemetostat is an oral, first-in-class EZH2 inhibitor being investigated in multiple ongoing clinical trials.

DRG and Zephyr Health Announce Partnership to Optimize the Commercial and Market Access Experience for Pharma Stakeholders

DRG and Zephyr Health Announce Partnership to Optimize the Commercial and Market Access Experience for Pharma Stakeholders

BURLINGTON, MA AND SAN FRANCISCO, CA, November 29, 2016 Decision Resources Group (DRG), a leading provider of proprietary data products and solutions to the healthcare industry, and Zephyr Health, the leading Insights-as-a-Service solution provider for life sciences companies, today announced a new strategic data and analytics partnership.

Strata Oncology Launches the Strata Trial with First Cancer Center Partners

Strata Oncology Launches the Strata Trial with First Cancer Center Partners

Expanding Access to NGS Tumor Sequencing and Targeted Therapy Trials for Advanced Cancer Patients

Ann Arbor, Michigan, December 16, 2016– Strata Oncology today announced launch of the Strata Trial, a nationwide observational study providing no-cost tumor sequencing and clinical trial matching for 100,000 advanced cancer patients, to study the impact of tumor sequencing on clinical trial enrollment.

Two Peer-Reviewed Publications Highlight Clinical Utility of PreTRM® Test

Two Peer-Reviewed Publications Highlight Clinical Utility of PreTRM® Test

Experts Predict a Reduction of Infant Mortality by 23.5% and Annual Direct Medical Costs of More Than $500 million Through Early Preterm Birth Risk Testing

SALT LAKE CITY, December 19, 2016- - Sera Prognostics, Inc., a women’s healthcare company, today announced the recent publications of two reports showing significant clinical utility of assessing preterm birth risk early in pregnancy with novel biomarker tests.

Sera Prognostics Enters into Agreement with LabCorp to be the Exclusive U.S. Distributor of PreTRM® Test

Sera Prognostics Enters into Agreement with LabCorp to be the Exclusive  U.S. Distributor of PreTRM® Test

LabCorp Leads $40 Million Series C Financing as Sera Expands its Activities to Address Premature Birth

SALT LAKE CITY, January 10, 2017– Sera Prognostics, Inc., a woman’s healthcare company, announced today that it has entered into a strategic collaboration with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a world leading life sciences company, to be the exclusive U.S. distributor of Sera’s PreTRM® test.

Terri L. Clevenger

Terri L. Clevenger

Immediately after college, Terri L. Clevenger began working in the bustling city of Boston, Massachusetts doing public relations work overseeing the ‘Concerts on the Common’ program for a local firm. It was 1983 and she was eager to show the world just how strong and capable an educated woman can be in the corporate world.

Research on Underlying Mechanisms of Pregnancy Complications and Medical Interventions Using Sera’s Proteomic Technology to be Presented at the Society for Maternal-Fetal Medicine’s 37th Annual Pregnancy Meeting

Research on Underlying Mechanisms of Pregnancy Complications and Medical Interventions Using Sera’s Proteomic Technology to be Presented at the Society for Maternal-Fetal Medicine’s 37th Annual Pregnancy Meeting

SALT LAKE CITY, January 23, 2017 --- Sera Prognostics, Inc., a women’s healthcare company, today announced the presentation of ongoing research evaluating the underlying mechanisms of significant pregnancy complications that result in preterm birth, use of progesterone as an intervention and employing Sera’s innovative proteomic technology platform to predict a woman’s risk for spontaneous and medically-indicated preterm birth.

Sera Prognostics Enters into Agreement with LabCorp to be the Exclusive U.S. Distributor of PreTRM® Test

Sera Prognostics Enters into Agreement with LabCorp to be the Exclusive  U.S. Distributor of PreTRM® Test

LabCorp Leads $40 Million Series C Financing as Sera Expands its Activities to Address Premature Birth

SALT LAKE CITY, January 10, 2017– Sera Prognostics, Inc., a woman’s healthcare company, announced today that it has entered into a strategic collaboration with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH), a world leading life sciences company, to be the exclusive U.S. distributor of Sera’s PreTRM® test.